We are discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world. Our ultimate goal for our patients is – Vision For Life.
In February 2022, Gyroscope Therapeutics became a Novartis company.
A new era of medicine
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of age-related macular degeneration (AMD) and gene therapy as a mode of sustained treatment delivery.
At Gyroscope, science is at the core of everything we do.
We are developing gene therapies beyond rare disease.
Developing surgical devices and procedures designed to deliver one-time ocular gene therapies.
Age-related macular degeneration is a leading cause of irreversible blindness in the elderly. Current treatment options may slow disease progression, but with a high treatment burden.
Our global management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at multiple innovative biotech and pharmaceutical companies.
Through our delivery system we also have significant surgical device development and surgeon training capabilities.